Scarica l'app Stockscreener
17.02
0.23%
-0.04
Dopo l'orario di chiusura:
17.02
Precedente Chiudi:
$17.06
Aprire:
$17.05
Volume 24 ore:
324.53K
Relative Volume:
0.52
Capitalizzazione di mercato:
$883.66M
Reddito:
$109.78M
Utile/perdita netta:
$114.54M
Rapporto P/E:
7.7202
EPS:
2.2046
Flusso di cassa netto:
$268.74M
1 W Prestazione:
-0.35%
1M Prestazione:
+0.65%
6M Prestazione:
+21.31%
1 anno Prestazione:
+24.78%
Intervallo 1D:
$17.00
$17.05
Intervallo di 1 settimana:
$17.00
$17.25
Portata 52W:
$13.08
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
17.02 | 885.73M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2026-03-04 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2025-12-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-12 | Iniziato | B. Riley Securities | Buy |
| 2024-08-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Iniziato | BTIG Research | Buy |
| 2024-01-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Iniziato | JP Morgan | Overweight |
| 2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Iniziato | Cowen | Outperform |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-29 | Ripresa | Piper Jaffray | Overweight |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-12-21 | Iniziato | Needham | Buy |
| 2016-11-03 | Iniziato | Piper Jaffray | Overweight |
| 2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Iniziato | Guggenheim | Buy |
| 2016-06-20 | Reiterato | Leerink Partners | Outperform |
| 2016-05-12 | Iniziato | Leerink Partners | Outperform |
| 2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Form 8K Theravance Biopharma Inc For: 10 September By Investing.com - Investing.com Canada
Theravance Bi in merger with Zymeworks faces shareholder suits, supplements proxy with disclosures - TradingView
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Theravance Biopharma Inc (NASDAQ: TBPH) Share Price, TBPH Stock News, TBPH Share Price & Updates - Kalkine
Theravance Biopharma Inc. (TBPH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
How (TBPH) Movements Inform Risk Allocation Models - Stock Traders Daily
Theravance Biopharma Inc. (TBPH) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Theravance Biopharma reports CYPRESS Phase 3 miss but FDA grants Type C meeting to discuss future trial - TradingView
Theravance Biopharma (NASDAQ:TBPH): What Could Its Scheduled Update Reveal? - Kalkine Media
Theravance (TBPH) Q1 2026 Scorecard: EPS Beats Its Estimate in the Current Update; Closing Move: The Stock Records a Flat ReactionForward EPS Estimate - vinanet.vn
Theravance Biopharma (TBPH) CEO logs 20K-share tax withholding - Stock Titan
Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan
Madison Avenue Partners, LP Trims Theravance Biopharma Inc (TBPH) Stake in Portfolio Rebalancing Move - GuruFocus
Theravance Biopharma, Inc. Revenue Breakdown – NASDAQ:TBPH - TradingView
Theravance (TBPH) Update: Rises 0.18% to $16.98 on the Day; Price Setup: Traders Can Monitor the $16.13-$17.83 RangeSupport Level Bounce - vinanet.vn
Theravance Biopharma (TBPH) Edges Higher to $16.97, Trapped Between Key Support and ResistanceFactor Valuation - vinanet.vn
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders - mykxlg.com
Theravance Biopharma Deal Faces Investor Probe - stl.news
Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma (TBPH) Holds Steady at $16.97 as Traders Eye Range-Bound MoveCovered Call Trade - vinanet.vn
Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A - Stock Titan
Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake - Stock Titan
(TBPH) Risk Channels and Responsive Allocation - Stock Traders Daily
Theravance Biopharma (TBPH) Stock Caught Between Fading Gains And Royalty Doubts - Sahm
Theravance Biopharma Announces Q2 2026 Financial Results with $10.8M Net Loss Amid Restructuring - Kalkine Media
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView
Theravance Biopharma (NASDAQ: TBPH) details $17 cash payout and ampreloxetine CVRs in Zymeworks deal - Stock Titan
Theravance Biopharma, Inc. 2026: Revenue $20.73M, EPS ($0.11) — 10-Q Summary - TradingView
Theravance Biopharma (TBPH) agrees $17 cash sale to Zymeworks plus CVRs - Stock Titan
Renaissance Technologies LLC Acquires New Holdings in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma earnings missed by $0.17, revenue fell short of estimates - Investing.com Canada
Theravance Biopharma Releases Q2 2026 Financial Results - AlphaStreet
Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY - Bitget
Theravance Biopharma Q2 Results: Adj. EPS beats by 260% - scanx.trade
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations - MarketBeat
Form 8K Theravance Biopharma Inc For: 10 August By Investing.com - Investing.com Australia
TBPH Looks 29.8% Undervalued on GF Value™ Amid Acquisition News - GuruFocus
Theravance Biopharma Swings to Net Loss in Q2, Revenue Falls - marketscreener.com
Earnings Flash (TBPH) Theravance Biopharma Posts Q2 Net Loss $0.11 a Share, vs. FactSet Est of $0.07 EPS - marketscreener.com
Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q2 Revenue $20.7M, vs. FactSet Est of $22.5M - marketscreener.com
Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash - TradingView
Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates - TradingView
Theravance Bio: Q2 Earnings Snapshot - marketscreener.com
BRIEF-Theravance Biopharma Q2 Operating Income USD -8.277 Million - TradingView
THERAVANCE BIOPHARMA Q2 OPERATING INCOME USD -8.277 MILLION - Moomoo
Press Release: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Strong Revenue Growth and High ROE Offer Intriguing Investment Prospects - DirectorsTalk Interviews
Theravance Biopharma (TBPH) Expected to Announce Earnings on Tuesday - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
(TBPH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):